Overview

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Status:
Completed

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

BB 1101
Chlorpheniramine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Rituximab